Dimethyl Sulfoxide
Apexbio Technology LLC Bromodomain Inhibitor, (+)-JQ1 1268524-70-4 10mM (in 1mL DMSO)
( )-JQ1 is a selective small-molecule inhibitor targeting BET (bromodomain and extraterminal) protein family members particularly BRD4 It competitively binds the acetyl-lysine recognition domain of BRD4 bromodomains 1 and 2 with reported Kd values of approximately 50 nM and 90 nM respectively By selectively inhibiting BET proteins ( )-JQ1 disrupts transcriptional regulatory processes essential in cancer biology rendering it a useful research tool for examining chromatin remodeling and gene expression patterns associated with tumor pathogenesis Additionally ( )-JQ1 specifically targets the testis-specific bromodomain protein BRDT enabling investigations into male reproductive biology by reversibly impairing spermatogenesis
Apexbio Technology LLC (+)-MK 801(Synonyms: Dizocilpine, Dizocilpine maleate, MK-801, (+)-MK-801, (+)-Dizocilpine), 10mM (in 1mL DMSO), CAS: 70449-94-4.
( )-MK 801 (CAS 70449-94-4) is a potent selective and non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor displaying a Ki of approximately 30 5 nM This small molecule readily crosses the blood-brain barrier and interacts reversibly with specific binding sites on cortical membranes predominantly localized within the hippocampus In vitro assays utilizing rat cortical slice preparations indicate that ( )-MK 801 robustly inhibits NMDA-induced depolarization events and suppresses epileptiform activity mediated by neurotoxic agents Due to these pharmacological properties ( )-MK 801 is utilized experimentally in neuroscience research to study NMDA receptor-mediated events neurotoxicity convulsions and excitatory neurotransmission pathways
Apexbio Technology LLC Ticagrelor 274693-27-5 10mM (in 1mL DMSO)
Ticagrelor (CAS 274693-27-5) is an orally active reversible antagonist targeting the platelet P2Y12 receptor By competitively binding to P2Y12 ticagrelor inhibits ADP-mediated platelet aggregation resulting in dose-dependent suppression of platelet activation and thrombosis in vitro Unlike other P2Y12 inhibitors requiring metabolic activation ticagrelor acts without metabolic transformation though it is primarily metabolized by CYP3A4 and CYP2C19 enzymes This compound is frequently employed in biomedical research exploring platelet function thrombosis mechanisms and drug-drug interactions involving cytochrome P450 enzymes
Apexbio Technology LLC Canagliflozin(Synonyms: Invokana, TA-7284, JNJ-28431754, Sulisent, Canagliflozin hemihydrate), 10mM (in 1mL DMSO), CAS: 842133-18-0.
Canagliflozin (CAS 842133-18-0) is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) a transporter responsible for renal glucose reabsorption By inhibiting SGLT2 activity Canagliflozin decreases renal glucose reabsorption resulting in increased urinary glucose excretion In CHO cells expressing human rat or mouse SGLT2 Canagliflozin potently inhibits sodium-dependent glucose uptake with IC50 values of 4 4 3 7 and 2 0 nM respectively Animal studies using db/db mice and Zucker diabetic fatty (ZDF) rats demonstrate dose-dependent reductions in blood glucose as well as decreased respiratory exchange ratio and body weight Canagliflozin is suitable for in vivo research through oral administration
Medchemexpress LLC Carbocysteine sulfoxide | 5439-87-2 | MFCD21364079 | 99.0% | 195.19 g/mol | C5H9NO5S | 10 MG
Carbocysteine sulfoxide is a small-molecule impurity of carbocisteine intended for research use. The substance is identified by CAS number 5439-87-2, has the molecular formula C5H9NO5S, and a molecular weight of 195.19 g/mol. It is provided in small-mass packages for laboratory and analytical applications.
- Used as an impurity reference for analytical method development.
- Supplied in small-mass packages suitable for laboratory research.
- Identified by CAS number 5439-87-2 for substance tracking.
- Molecular formula C5H9NO5S and molecular weight 195.19 g/mol.
- Intended for research use only; not for human or clinical use.
Apexbio Technology LLC Cyclophosphamide 50-18-0 10mM (in 1mL DMSO)
Cyclophosphamide is a nitrogen mustard alkylating prodrug activated via hepatic enzymes to its active metabolites These metabolites alkylate DNA primarily at guanine residues resulting in DNA cross-linking strand breaks and mutations consequently triggering cytotoxic effects Cyclophosphamide exhibits cytotoxicity in vitro with an IC50 of 37 6 M in mouse embryo BALB/c 3T3 cells and an IC50 of 8 79 M against human HL60 cells It impacts immune regulation by decreasing regulatory T cell counts and suppressive marker expression (FoxP3 GITR) facilitating immune response modulation Commonly applied in cancer and immunological research cyclophosphamide is also employed in genotoxicity assays due to its capacity to induce chromosomal aberrations and mutations
Apexbio Technology LLC Pomalidomide (CC-4047) 19171-19-8 10mM (in 1mL DMSO)
Pomalidomide (CC-4047) an immunomodulatory derivative structurally related to Thalidomide exhibits anti-tumor and anti-angiogenic properties Chemically the molecule is distinguished by additional amino substituent at the fourth position of the phthalimide ring and two extra oxy groups Its mechanism of action includes modulation of specific cytokines within the tumor microenvironment (TNF- IL-6 IL-8 VEGF) suppression of tumor cell proliferation and modification of host immune cell activity Pomalidomide is widely studied in biomedical research particularly in therapeutic exploration for hematologic malignancies such as multiple myeloma including relapsed or refractory disease states
Apexbio Technology LLC D4476 301836-43-1 10mM (in 1mL DMSO)
D4476 (CAS 301836-43-1) is a selective cell-permeable inhibitor of casein kinase 1 (CK1) and ALK5 exhibiting IC50 values of 0 3 M for CK1 and 0 5 M for ALK5 (at 0 1 mM ATP in vitro) It likely acts via ATP-competitive inhibition of CK1 showing minimal to no significant inhibitory activity against SAPK2a/p38 PKB or SGK Treatment with D4476 inhibits CK1-mediated phosphorylation of FOXO1a (Ser322 and Ser325) and RhoB (Ser185) in H4IIE and HeLa cells respectively impacting downstream processes such as nuclear export dynamics and actin cytoskeleton regulation Additionally it induces partial p53-dependent growth arrest in HCT116 cells
Apexbio Technology LLC Ambrisentan 177036-94-1 10mM (in 1mL DMSO)
Ambrisentan (CAS 177036-94-1) is an orally active selective endothelin receptor antagonist specifically targeting ETA receptors It exhibits strong selectivity towards ETA over ETB receptor subtypes shown by Ki values of approximately 1 nM for recombinant ETA receptors expressed in vitro versus 195 nM for ETB In recombinant human receptor assays using intact cells this selectivity is enhanced with reported Ki values of 0 63 nM (ETA) and 48 7 nM (ETB) Pharmacologically ambrisentan s selective ETA blockade preserves the ETB receptor s intrinsic vasodilatory and endothelin clearance functions making it useful in research involving pulmonary arterial hypertension cerebrovascular conditions and ischemia-reperfusion injury
Apexbio Technology LLC Linezolid(Synonyms: Zyvox, Zyvoxid, U-100766, PNU-100766, U-100766E, PNU100766, Linezolide), 10mM (in 1mL DMSO), CAS: 165800-03-3.
Linezolid (CAS 165800-03-3) is a synthetic oxazolidinone antimicrobial compound with broad-spectrum activity primarily against Gram-positive bacteria including multi-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) vancomycin-resistant Enterococcus (VRE) and penicillin-resistant Streptococcus pneumoniae Linezolid inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit thereby preventing formation of the functional 70S initiation complex In cell-free transcription-translation assays using E coli linezolid demonstrates an IC50 of approximately 1 8 mM Due to its pharmacokinetics and high oral bioavailability linezolid is widely utilized in clinical research related to complicated skin infections and bacterial pneumonia
![Apexbio Technology LLC Scriptaid(Synonyms: Scriptaid, HDAC inhibitor Scriptaid, 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide), 10mM (in 1mL DMSO), CAS: 287383-59-9.](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000060690.PNG-250.jpg)
Apexbio Technology LLC Scriptaid(Synonyms: Scriptaid, HDAC inhibitor Scriptaid, 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide), 10mM (in 1mL DMSO), CAS: 287383-59-9.
Scriptaid (CAS 287383-59-9) is a small-molecule histone deacetylase (HDAC) inhibitor originally identified through high-throughput transcriptional screening It specifically targets class I HDAC isoforms inhibiting HDAC1/HDAC3 and HDAC8 with IC50 values of approximately 0 6 M and 1 M respectively Structurally related to other hydroxamic acid-containing HDAC inhibitors such as TSA Scriptaid consists of a hydroxamic acid moiety a connecting linker and an aromatic cap group In glioblastoma (GBM) research Scriptaid shows promise by inducing apoptosis in glioma cells highlighting its potential utility for oncology-focused investigations
Apexbio Technology LLC Erlotinib 183321-74-6 10mM (in 1mL DMSO)
Erlotinib (CAS 183321-74-6) is an orally bioavailable reversible inhibitor targeting the epidermal growth factor receptor (EGFR) tyrosine kinase It acts by competitively binding the intracellular ATP-binding domain of EGFR thereby preventing receptor autophosphorylation and subsequent signaling cascades involved in proliferation angiogenesis and cell survival In biochemical assays Erlotinib demonstrates potent inhibition of EGFR tyrosine kinase (IC50 2 nmol/L) and cellular autophosphorylation of EGFR (IC50 20 nmol/L) Due to its selective interference with EGFR-mediated signaling Erlotinib is extensively employed in oncology research particularly in studies on EGFR-expressing tumor models
Medchemexpress LLC S63845 Solution, 10 mM * 1 mL in DMSO
S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1.
Apexbio Technology LLC Pranlukast 103177-37-3 10mM (in 1mL DMSO)
Pranlukast (CAS 103177-37-3) is a selective antagonist of cysteinyl leukotriene (cysLT) receptors exhibiting its pharmacological action by competitively binding to targeted leukotriene receptor sites It specifically prevents the interaction of endogenous leukotrienes (LTC4 LTD4 LTE4) with corresponding receptors located on pulmonary cell membranes thus reducing leukotriene-driven airway inflammation and bronchoconstriction Binding experiments demonstrate that pranlukast possesses notably greater affinity for LTE4 and LTD4 compared to LTC4 In biomedical research pranlukast is frequently utilized for mechanistic studies and pharmacological modeling of asthma allergic rhinitis and related airway inflammatory conditions